Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode™ Whole Transcriptome ...
BostonGene, developer of the leading AI foundation model for tumor and immune biology, announced results from the FEASY study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results